Technology area: Biotechnology & Pharmaceuticals
13 pending office actions • 5 clients • 12 examiners • 10 art units • 0 of 13 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
POLSINELLI and DUKE UNIVERSITY has 13 pending office actions in Biotechnology & Pharmaceuticals and 493 career applications. The current workload sits within a focused institutional application history in the same technology area.
The resolved allowance rate is 71.57%, and the average is 4.19 office actions per allowance. The outcome rate indicates that allowance was achieved in a smaller share of resolved matters than an outcome record with a higher rate would show, while the action average reflects substantial examination activity before allowance. Clients can use this profile to assess biotechnology prosecution where complex or persistent office-action work may be part of the process.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (23%) |
| §103 only | 2 (15%) |
| §112 only | 1 (8%) |
| Double-patenting + other | 2 (15%) |
| Multi-statute (no §101) | 5 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRABER, JAMES J | 2 | 46.5% | +57.6% |
| MI, QIUWEN | 1 | 68.4% | +50.0% |
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.4% |
| ZOU, NIANXIANG | 1 | 64.0% | +25.0% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
| CHENG, KAREN | 1 | 76.4% | +26.6% |
| ARMATO JR, DENNIS IGNATIUS | 1 | 42.9% | +80.0% |
| KELLY-O'NEILL, YOLANDA LYNNETTE | 1 | 31.8% | +23.7% |
| DENT, ALANA HARRIS | 1 | 44.1% | +32.2% |
| CORDAS, EMILY ANN | 1 | 50.9% | +57.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575412 | Compositions For and Methods of Promoting Respiratory Health | ARMATO JR, DENNIS IGNATIUS | 4d overdue |
| 17919997 | COMPOSITIONS AND METHODS FOR FORMATION AND SECRETION OF EXTRACELLULAR VESICLES AND AAV PARTICLES | SIFFORD, JEFFREY MARK | 2d overdue |
| 17637760 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | GRABER, JAMES J | 15d |
| 18024091 | METHODS FOR REPROGRAMMING TARGET CELLS | CORDAS, EMILY ANN | 27d |
| 18849279 | COMPOSITIONS FOR AND METHODS OF MODULATING RNA STABILITY | JACKSON, SHAWQUIA | — |
| 18883669 | Compositions For and Methods of Treating Influenza | ZOU, NIANXIANG | — |
| 18626187 | ANTIBIOTICS COMPRISING LPXH-TARGETING COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CHENG, KAREN | — |
| 18547332 | Compositions For and Methods of Improving Gene Therapy | GRABER, JAMES J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575412 | Compositions For and Methods of Promoting Respiratory Health | ARMATO JR, DENNIS IGNATIUS | 4d overdue |
| 17637760 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | GRABER, JAMES J | 15d |
| 18312719 | SYSTEMS AND METHODS FOR PROMOTING REMYELINATION WITH FACTORS DERIVED FROM UMBILICAL CORD BLOOD MACROPHAGES | DENT, ALANA HARRIS | 20d |
| 18024091 | METHODS FOR REPROGRAMMING TARGET CELLS | CORDAS, EMILY ANN | 27d |
| 18927395 | MODULAR BIOMATERIAL PLATFORM LOCAL, INJECTABLE DELIVERY OF A DRUG AND METHODS OF MAKING AND USING SAME | MI, QIUWEN | — |
| 18883669 | Compositions For and Methods of Treating Influenza | ZOU, NIANXIANG | — |
| 18662751 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | NOTTINGHAM, KYLE GREGORY | — |
| 18626187 | ANTIBIOTICS COMPRISING LPXH-TARGETING COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CHENG, KAREN | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Duke University | 9 |
| Harvard University | 1 |
| Sisu Pharma, Inc. | 1 |
| Lurie Children's Hospital | 1 |
| NATIONAL UNIVERSITY OF SINGAPORE | 1 |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1631 | 2 |
| 1626 | 1 |
| 1621 | 1 |
| 1623 | 1 |
| 1651 | 1 |
| 1692 | 1 |
| 1643 | 1 |
| 1632 | 1 |
| 1624 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18927395 | MODULAR BIOMATERIAL PLATFORM LOCAL, INJECTABLE DELIVERY OF A DRUG AND METHODS OF MAKING AND USING SAME | Duke University | MI, QIUWEN | §112 | Non-Final OA | — | Pending | Oct 25, 2024 | |
| 18849279 | COMPOSITIONS FOR AND METHODS OF MODULATING RNA STABILITY | Duke University | JACKSON, SHAWQUIA | 1626 | §102§112 | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18883669 | Compositions For and Methods of Treating Influenza | President and Fellows of Harvard College | ZOU, NIANXIANG | 1671 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 12, 2024 |
| 18662751 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Sisu Pharma, Inc. | NOTTINGHAM, KYLE GREGORY | 1621 | §102DP | Non-Final OA | — | Pending | May 13, 2024 |
| 18626187 | ANTIBIOTICS COMPRISING LPXH-TARGETING COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Duke University | CHENG, KAREN | 1623 | §102§103 | Non-Final OA | — | Pending | Apr 03, 2024 |
| 18575412 | Compositions For and Methods of Promoting Respiratory Health | Ann & Robert H. Lurie Children's Hospital of Chicago | ARMATO JR, DENNIS IGNATIUS | 1651 | §101§102§103§112 | Final Rejection | 4d overdue | Pending | Dec 29, 2023 |
| 18547332 | Compositions For and Methods of Improving Gene Therapy | Duke University | GRABER, JAMES J | 1631 | §102§103 | Non-Final OA | — | Pending | Aug 21, 2023 |
| 18200156 | Methods and Compositions for the Treatment of Steatosis-Associated Disorders | National University Of Singapore | KELLY-O'NEILL, YOLANDA LYNNETTE | 1692 | §103 | Final Rejection | — | Pending | May 22, 2023 |
| 18312719 | SYSTEMS AND METHODS FOR PROMOTING REMYELINATION WITH FACTORS DERIVED FROM UMBILICAL CORD BLOOD MACROPHAGES | Duke University | DENT, ALANA HARRIS | 1643 | §102§103DP | Final Rejection | 20d | Pending | May 05, 2023 |
| 18024091 | METHODS FOR REPROGRAMMING TARGET CELLS | Duke University | CORDAS, EMILY ANN | 1632 | §102§103 | Final Rejection | 27d | Pending | Mar 01, 2023 |
| 17919997 | COMPOSITIONS AND METHODS FOR FORMATION AND SECRETION OF EXTRACELLULAR VESICLES AND AAV PARTICLES | Duke University | SIFFORD, JEFFREY MARK | 1671 | §101§102§103§112 | Final Rejection | 2d overdue | Pending | Oct 19, 2022 |
| 17912429 | COMPOSITIONS AND METHODS FOR TREATMENT OF PATHOLOGIC PAIN ASSOCIATED WITH MALIGNANT GROWTH DISORDER | Duke University | MOORE, SUSANNA | 1624 | §103 | Final Rejection | — | Pending | Sep 16, 2022 |
| 17637760 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH | Duke University | GRABER, JAMES J | 1631 | §103§112 | Final Rejection | 15d | Pending | Feb 23, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial71.6% of resolved applications prosecuted by Polsinelli And Duke University were allowed, across 493 applications in USPTO records.
4.19 office actions per allowed application on average.
13 pending office actions as of October 2026, for 5 clients, before 12 examiners in 10 art units.
